HROW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harrow Inc (HROW) is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock has constructive long-term catalysts, but the current setup is not clean enough to justify an immediate buy at this price. My direct view: hold and wait for either a better entry or clearer confirmation of sustained upside.
HROW closed at 42.28, slightly below the previous close of 42.74, showing mild near-term weakness. The MACD histogram is positive at 0.233 but contracting, which suggests bullish momentum is fading. RSI_6 is 65.426, near the upper-neutral range and not yet deeply overbought. Moving averages are converging, implying the stock is in a consolidation phase rather than a strong trend. Key levels: pivot 42.626, resistance at 44.348 and 45.413, support at 40.903 and 39.838. The short-term pattern data also points to weakness: 40% chance of -1.24% next day and -4.53% next month. Overall, the chart is neutral-to-slightly bearish in the very short term.
Recent positive catalysts include Samsung Bioepis partnering with Harrow to commercialize ophthalmology biosimilars BYOOVIZ and OPUVIZ in the U.S., and Harrow launching BYOOVIZ as the first FDA-approved ophthalmic biosimilar for retinal diseases. Analyst commentary also highlights improving momentum in IHEEZO and Triesence, upcoming product and coding catalysts, and expanding commercial leverage that could support stronger second-half growth.
The main negative catalyst is weaker VEVYE pricing, which has already led to revised growth expectations and lower revenue forecasts from analysts. The stock also lacks strong immediate technical confirmation, with momentum fading and the recent pattern suggesting possible near-term downside. Option flow is mixed despite bullish positioning, and the latest price action was slightly negative on the day.
No usable latest-quarter financial snapshot was provided due to a data error, so a full quarter-by-quarter financial assessment is not available. From the analyst notes, Q1 results were weighed down by weaker VEVYE pricing, but underlying volume trends were improving, and analysts expect accelerating second-half growth. The most recent discussion points to revenue growth being timing-related rather than demand-driven, which is constructive for the medium term but not enough to call the current entry attractive for a beginner today.
Analyst sentiment is still positive overall, with B. Riley maintaining Buy and Cantor Fitzgerald maintaining Overweight. However, price targets have been reduced recently: B. Riley cut its target to $60 from $65 on 2026-05-14 and previously to $65 from $74 on 2026-04-07, while Cantor Fitzgerald cut its target to $88 from $91 on 2026-05-13. The Wall Street pros view is bullish on the long-term story but cautious on near-term pricing and growth timing. No recent politician or Congress trading data was available.
